In April 2018, LaserGen, Inc. was aquired by Agilent Technologies Inc (NYSE: A) for $105M. LaserGen, Inc. is a biotechnology company focused on commercializing novel technologies in nucleotide chemistry and next-generation genomic sequencing. The firm has strong research collaborations with Baylor College of Medicine and Rice University. Through collaboration, technology, and license agreements, LaserGen has begun developing a proprietary platform for DNA sequencing of whole genomes that will (1) provide new capabilities, significant cost savings, and efficiency gains for the research market and (2) provide rapid, portable diagnoses of common diseases in the clinical setting. The technology platforms rest on development of novel fluorescent nucleotides for application of a sequencing-by-synthesis (SBS) method and development of a novel method of fluorescent detection using Pulsed Multiline Excitation (PME). Lasergenâs key technology, Lightning Terminatorsâ¢, provides unique photocleavable terminator chemistry with faster reaction kinetics and robust cleavage properties. The benefits extend beyond their original design in enhanced next-generation sequencing to include applications in genomics, proteomics and transcriptomi
